Table 1.

Patient characteristics

Characteristic	BRONJ (N=25)	Non-BRONJ (N=48)	P-value
Age - mean (sd), in years	66.3 (10.3)	64.4 (11.7)	0.50
Sex – no. (%)
Female	16 (64%)	34 (71%)	0.60
Race – no. (%)			1.00
White	24 (96%)	46 (96%)
Black	1 (4%)	2 (4%)
Malignant Disease – no. (%)			0.020
Breast cancer	13 (52%)	27 (56%)
Multiple myeloma	4 (16%)	15 (31%)
Prostate cancer	2 (8%)	6 (13%)
Lung cancer	2 (8%)	0 (0%)
Renal cell carcinoma	3 (12%)	0 (0%)
Others	1 (4%)	0 (0%)
Pre-existing medical conditions – no. (%)
Diabetes mellitus	1 (4%)	5 (10%)	0.66
Hypertension	11 (44%)	26 (54%)	0.47
Hypercholesterolemia/Hyperlipidemia	11 (44%)	15 (33%)	0.45
Hypothyroidism	7 (28%)	10 (21%)	0.56
Previous medications – no. (%)
Corticosteroids	14 (56%)	32 (67%)	0.45
Smoking Status – no. (%)			0.11
Current	5 (20%)	3 (6%)
Former	11 (44%)	18 (38%)
Never	9 (36%)	27 (56%)
Type of Bisphosphonates – no. (%)			0.71
Zoledronate	16 (64%)	32 (67%)
Pamidronate	2 (8%)	6 (13%)
Pamidronate + Zoledronate	7 (28%)	10 (21%)
Bisphosphonate infusions – mean (sd)
All cancer	38.4 (26.3)	18.8 (7.2)	< 0.0001
Duration of Bisphosphonate exposure – mean (sd) in months
All cancer	45.1 (29.7)	37.7 (21.9)	0.23